Jacqueline L. Norris-Drouin

Jacqueline L. Norris-Drouin

Auto-generated profile, based on publicly available information

Jacqueline L. Norris-Drouin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2020 in Molecules
Verified
Journal Article
Open access
PDF file
JRJustin Rectenwald
Justin Rectenwald
SGShiva Krishna Reddy Guduru
Shiva Krishna Reddy Guduru
ZDZhao Dang
Zhao Dang
LCLeonard B. Collins
Leonard B. Collins
YLYi-En Liao
Yi-En Liao
Kenneth PearceKenneth Pearce
Kenneth Pearce
Chromatin structure and function, and consequently cellular phenotype, is regulated in part by a network of chromatin-modifying enzymes that place post-translational modifications (PTMs) on histone tails. These marks serve as recruitment sites for other chromatin regulatory complexes that ‘read’ these PTMs. High-quality chemical probes that can block reader functions of proteins involved in chromatin regulation are important tools to improve our understanding of pathways involved in chromatin dynamics. Insight into the intricate system of chromatin PTMs and their context within the epigenome is also therapeutically important as misregulation of this complex system is implicated in numerous human diseases. Using computational methods, along with structure-based knowledge, we have designed and constructed a focused DNA-Encoded Library (DEL) containing approximately 60,000 compounds targeting bi-valent methyl-lysine (Kme) reader domains. Additionally, we have constructed DNA-barcoded control compounds to allow optimization of selection conditions using a model Kme reader domain. We anticipate that this target-class focused approach will serve as a new method for rapid discovery of inhibitors for multivalent chromatin reader domains.

Verified
Journal Article
Open access
PDF file
EHEmily A. Hull-Ryde
Emily A. Hull-Ryde
JMJohn T. Minges
John T. Minges
MMMary Martino
Mary Martino
TKTakafumi Kato
Takafumi Kato
JNJacqueline L. Norris-Drouin
Jacqueline L. Norris-Drouin
Carla RibeiroCarla Ribeiro
Carla Ribeiro
New anti-inflammatory treatments are needed for CF airway disease. Studies have implicated the endoplasmic reticulum stress transducer inositol requiring enzyme 1α (IRE1α) in CF airway inflammation. The activation of IRE1α promotes activation of its cytoplasmic kinase and RNase, resulting in mRNA splicing of X-box binding protein-1 (XBP-1s), a transcription factor required for cytokine production. We tested whether IRE1α kinase and RNase inhibition decreases cytokine production induced by the exposure of primary cultures of homozygous F508del CF human bronchial epithelia (HBE) to supernatant of mucopurulent material (SMM) from CF airways. We evaluated whether IRE1α expression is increased in freshly isolated and native CF HBE, and couples with increased XBP-1s levels. A FRET assay confirmed binding of the IRE1α kinase and RNase inhibitor, KIRA6, to the IRE1α kinase. F508del HBE cultures were exposed to SMM with or without KIRA6, and we evaluated the mRNA levels of XBP-1s, IL-6, and IL-8, and the secretion of IL-6 and IL-8. IRE1α mRNA levels were up-regulated in freshly isolated CF vs. normal HBE and coupled to increased XBP-1s mRNA levels. SMM increased XBP-1s, IL-6, and IL-8 mRNA levels and up-regulated IL-6 and IL-8 secretion, and KIRA6 blunted these responses in a dose-dependent manner. Moreover, a triple combination of CFTR modulators currently used in the clinic had no effect on SMM-increased XBP-1s levels coupled with increased cytokine production in presence or absence of KIRA6. These findings indicate that IRE1α mediates cytokine production in CF airways. Small molecule IRE1α kinase inhibitors that allosterically reduce RNase-dependent XBP-1s may represent a new therapeutic strategy for CF airway inflammation.

4 December 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
BCBeatrice Chiew
Beatrice Chiew
MGMenachem J. Gunzburg
Menachem J. Gunzburg
CFCaroline A. Foley
Caroline A. Foley
HZHong Zeng
Hong Zeng
ADAiping Dong
Aiping Dong
LJLindsey I. James
Lindsey I. James
53BP1 is a DNA damage response protein recruited to sites of double strand breaks through recognition of dimethylated lysine on histone 4 by its tandem Tudor domains. Like 53BP1, BRCA-1 plays a role in the regulation of DNA repair pathways, and BRCA-1 mutations have been strongly linked to breast and ovarian cancer. Interestingly, mice null for 53BP1 and BRCA-1 genes display minimal tumor formation, suggesting that the effects of deleterious BRCA-1 mutations could be prevented with potent 53BP1 small molecule antagonists. Herein, we describe a fragment screen that was used to identify compounds that bind to the 53BP1 Tudor domain and a chemoinformatic workflow to select near-neighbour analogues and establish Structure Activity Relationships for these binders. The marked affinity improvements of the analogues over their parent fragments highlights the developability of these series and the utility of this approach in discovering novel hit compounds for 53BP1 and other methyl-lysine reader proteins.